Aspire Biopharma Holdings, Inc. (ASBP) Stock Price & Analysis

Aspire Biopharma Holdings, Inc. (ASBP) fell 4.11% to USD 8.87 as of September 8, 2026 at 10:53 UTC, according to Nexqual real-time market data.

ASBP last closed at USD 8.87; the session ranged USD 8.8–9.5 on volume of 42,258 shares. Market capitalization is —, with a 52-week range of USD 0.11–18.88 (NCM). Source: Nexqual, September 8, 2026 at 10:53 UTC.

Key Statistics (as of September 8, 2026 at 10:53 UTC)

Technical Analysis (ASBP)

Nexqual's technical model rates ASBP "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 10:53 UTC.

From Aspire Biopharma Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.   Any patents granted from national/regional phase applications of International Application No.
• A second patent application was filed in October 2024 for a high-dose version of our sublingually administered aspirin product (application number 63/702,381) using a micelle variation on our technology which can be used with a variety of substances.   In the initial development launch of its aspirin product, Aspire has focused on the delivery of aspirin, which may be the most studied and accepted analgesic and anti-inflammatory drug on the market.

Partnerships

• We have also entered into a manufacturing agreement with Microsize, a contract development and manufacturing organization or ("CDMO") in Quakertown, PA in January 2026 to manufacture aspirin products for the next round of clinical trials of the high-dose aspirin for myocardial infarction.   We used drug product manufactured by Glatt to conduct clinical trials to support approval of a section 505(b)(2) New Drug Application ("NDA") for the aspirin product.
• In addition, we have entered into a fill-and-finish agreement with a contract manufacturer to convert the aspirin product manufactured by Glatt into packaged drug product that can be utilized in clinical trials.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:53 UTC. This page is informational and not investment advice.